肌肉减少症治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00010491
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 134
Buy Now

【研究报告】肌肉减少症治疗市场规模预计将从2022年的33.9762亿美元增长到2030年的52.6476亿美元;预计 2022 年至 2030 年市场复合年增长率为 5.6%。
市场洞察和分析师观点:
老年人口激增以及成年人营养不良和维生素缺乏症的增加是推动这一趋势的关键因素市场增长。然而,直接干预措施的缺乏阻碍了肌肉减少症治疗市场的进展。营养不良是肌肉减少症的主要危险因素之一。据世界卫生组织 (WHO) 统计,截至 2021 年,全球约有 23 亿成年人营养不良,占全球人口的近 30%。在已报告的危险因素中,蛋白质能量缺乏是肌肉减少症的常见原因。此外,维生素 D 缺乏或不足与多种疾病的风险增加呈正相关,例如癌症、肥胖、心血管疾病和肌肉减少症。根据美国国立卫生研究院 (NIH) 的数据,全球近 50% 的人口缺乏维生素 D,约 10 亿人缺乏维生素 D。在美国,超过 35% 的成年人缺乏维生素 D。
增长动力:
老年人群容易出现肌肉减少症、骨科疾病、代谢紊乱和神经系统疾病等。肌肉减少症是一种由骨骼肌质量和强度逐渐丧失引起的老年性疾病。它与不利健康结果的较高风险相关,例如跌倒、残疾、收容、生活质量差和死亡。发达国家的老年人口正在迅速增加。根据世界卫生组织 (WHO) 的数据,到 2050 年,全球老龄化人口可能会从 2019 年的约 10 亿增加到约 21 亿。根据国家医学图书馆的数据,中国的老年人口正以全球老龄化速度之一的速度增长。世界上最快的费率。到2040年,预计28%的中国人口年龄在60岁以上。根据日本全国数据,该国 1.25 亿人口中有 29.1% 年龄在 65 岁或以上。根据 2020 年人口普查,1920 年至 2020 年期间,美国 65 岁及以上人口的增长速度约为总人口的五倍。 2020年,老年人口数量达到5580万,占美国总人口的16.8%。
衰老导致肌肉质量减少,这是身体成分的主要变化之一。老年人食物消耗的显着下降是导致肌肉质量损失的关键因素之一。根据美国国家医学图书馆的数据,50-60岁年龄段的人每年损失近1.5%的肌肉力量,而60岁以后每年损失1-2%的肌肉质量。与一般人群相比,老年人患者肌肉减少症的患病率较高。根据 Elsevier 2023 年 6 月发表的一篇文章,肌肉减少症的患病率从糖尿病患者的 18% 到无法治愈的食管癌患者的 66% 不等。因此,老年人口的增加对肌肉减少症治疗市场的增长做出了重大贡献。
没有一种经批准的药物可以直接用于治疗肌肉减少症。这也可以归因于这样一个事实:最初有希望的途径无法得到良好实施的随机对照试验的任何综合结果的支持。因此,缺乏直接针对肌肉减少症的治疗方案阻碍了肌肉减少症治疗市场的增长。
战略见解
报告细分和范围:
肌肉减少症治疗市场已根据治疗类型和分销渠道进行细分。根据治疗类型,市场分为维生素 D 和钙补充剂、蛋白质补充剂、维生素 B12 补充剂等。肌肉减少症治疗市场根据分销渠道分为药店、零售渠道、在线渠道等。该市场根据地理位置分为北美(美国、加拿大和墨西哥)、欧洲(法国、德国、意大利、英国、西班牙和欧洲其他地区)、亚太地区(澳大利亚、中国、日本、印度、韩国、亚太地区其他地区)、中东和非洲(沙特阿拉伯、阿联酋、南非以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)。
细分分析:
肌肉减少症治疗市场按治疗类型分为维生素 D 和钙补充剂、蛋白质补充剂、维生素 B12 补充剂等。维生素 D 和钙补充剂细分市场在 2022 年占据最大市场份额。预计该细分市场的肌少症治疗市场在 2022 年至 2030 年期间将创下 6.5% 的最高复合年增长率。维生素 D 是一种脂溶性维生素,对于维持钙稳态和健康的骨代谢至关重要。补充维生素 D 已被研究为一种降低肌肉减少症风险的有用饮食策略。维生素 D 水平欠佳的老年人极易患肌少症,通常与跌倒、住院和其他不良影响有关。
肌少症治疗市场,按治疗类型划分 – 2022 年和 2030 年
肌少症治疗市场,按分销渠道,细分为药店、零售渠道、在线渠道等。药房细分市场在 2022 年占据了相当大的市场份额。然而,预计在线渠道细分市场在 2022 年至 2030 年期间的复合年增长率将达到 6.4%,是最快的。补充剂可以作为非处方药在药店购买。市场上有许多由维生素 D、维生素 B12 和蛋白质补充剂等膳食补充剂组成的非处方药产品,这些产品是肌肉减少症治疗方案的一部分。
无现金交易是与进展相关的主要好处在线零售商,这有助于他们扩大在非大都市的影响力。销售肌肉减少症治疗产品补充剂的几个主要在线渠道是 apollo pharmacy、HealthKart 和 1mg。互联网用户数量的增加、接触多个品牌的便利性、快节奏的生活方式、24×7的各种产品供应以及购物平台的高可达性是推动肌少症补充剂通过在线渠道销售的关键因素.
区域分析:
根据地理位置,全球肌肉减少症治疗市场分为北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。 2022年,北美占据全球肌少症治疗市场的最大份额。亚太地区预计 2022 年至 2030 年复合年增长率最高。北美肌肉减少症治疗市场的增长归因于营养补充剂作为治疗选择的日益普及、骨科疾病患病率的飙升以及老年人群中维生素 B12 和维生素 D 缺乏病例的增加。
肌肉减少症北美的治疗市场进一步分为美国、加拿大和墨西哥。肌肉减少症的患病率因年龄和性别而异;居住在美国辅助生活设施或社区的老年人患这种疾病的风险较高。根据美国国立卫生研究院的数据,2019 年美国肌肉减少症患者的预计住院费用为 404 亿美元。平均而言,患有这种疾病的人每年比肌肉正常的人多支付 2,315 美元的住院费用质量和功能;他们住院的可能性几乎是没有肌肉减少症的人的两倍。研究表明,骨骼肌力量损失至少减少 10% 可以预防肌肉减少症,并为美国每年节省约 10 亿美元的医疗费用。
加拿大是肌肉减少症治疗增长最快的市场之一。该国的市场增长显而易见,每年都会报告大量骨科疾病病例,主要是由于维生素和营养缺乏所致。据加拿大公共卫生局(PHAC)统计,加拿大有超过230万人患有骨质疏松症。少肌症是骨质疏松症的重要原因之一。骨质疏松症是导致 50 岁及以上人群 80% 以上骨折的主要危险因素。维生素、钙和蛋白质在预防和治疗肌肉减少症方面发挥着重要作用。关于补充剂对骨骼健康益处的持续研究以及营养保健品的进步预计将在未来几年在加拿大产生对肌肉减少症治疗的巨大需求。
行业发展和未来机会:
在该行业运营的一些主要参与者肌肉减少症治疗市场越来越关注治疗肌肉减少症的药物开发。目前正在开发新的肌肉减少症治疗方法并进行临床试验。下面提到了其中一些产品:
临床开发中的肌肉减少症药物
公司名称
干预措施
条件
临床试验阶段
雅培营养
含 AN777 的医用食品
口服营养配方
营养不良
肌肉减少症
第 3 阶段
Nutricia Research
膳食补充剂:Bolus ONS A
膳食补充剂:Bolus ONS B
膳食补充剂:Bolus ONS C
>膳食补充剂:推注 ONS D
肌肉减少症
第 1 阶段
诺华制药
药物:Bimagrumab
肌肉减少症
第 2 阶段
麦克马斯特大学
行为:逐步减少
肌肉减少症
第 1 阶段
Metabolic Technologies Inc.
膳食补充剂:安慰剂
药物:HMB 加维生素 D
行为:非运动
行为:运动
肌肉减少症
第 1 阶段< br>Merck Sharp & Dohme LLC
药物:比较器 MK-077
药物:比较器安慰剂
肌少症
PHASE2
Immunotec Inc.
膳食补充剂:免疫
膳食补充剂:酪蛋白
衰老|肌少症
PHASE2
杨丽君
组合产品:3个月强化干预
肌少症
PHASE4
Regeneron Pharmaceuticals
药物:REGN1033 (SAR391786)< br>药物:安慰剂
肌肉减少症
第 2 阶段
资料来源:公司网站和 Insight Partners 分析
因此,处于不同临床开发阶段的药物管道不断延伸,为肌肉减少症治疗提供了重要机会市场增长。
竞争格局和主要公司:
Abbott Laboratories、Bayer AG、Metagenics LLC、Nestle Health Science SA、Novartis AG、Pfizer Inc.、Sanofi SA、Amway Corp、GSK Plc 和 Makers Nutrition LLC 是是肌肉减少症治疗市场的知名公司之一。这些公司专注于引进新技术、升级现有产品并扩大地理覆盖范围,以满足全球不断增长的消费者需求。
2023年10月,Metagenics LLC完成对Amipro Advanced Development Products 100%股份的收购。多年来,Ampiro 一直是 Metagenics LLC 产品在南非的独家经销商。此次收购加强了该公司在该国的分销网络,进一步使其能够在所有主要 EMEA 国家开展直接分销业务。 2023 年 9 月,Biophytis 获得美国食品和药物管理局 (FDA) 授权,在美国启动 SARA-31 研究。这是肌肉减少症治疗专业领域的首个 3 期研究。 2022 年 9 月,雅培实验室子公司雅培印度有限公司推出了新配方 Ensure with HMB。 Ensure with HMB 的推出旨在为印度老年人提供饮食支持。该产品采用特殊独家成分 β-羟基-β-甲基丁酸酯 (HMB) 配制而成,有助于对抗肌肉损失,恢复力量和能量。 2022 年 3 月,全球领先的运动营养和生活方式提供商 MusclePharm Corporation营养补充剂品牌扩大了其产品组合,推出了新的乳清蛋白饮料,增加了即饮蛋白类别。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which region is the fastest growing the sarcopenia treatment market?

Asia Pacific is expected to be the fastest growing region in the sarcopenia treatment market. Asia is the world’s most populated continent with a rapidly aging population, and sarcopenia-related issues are becoming more prevalent in several Asian countries. Asians lead extremely different lifestyles and follow different dietary habits than people from the Western world. In Asia, sarcopenia in older individuals is more common in males (prevalence 9.6–22.1%) than females (prevalence 7.7–21.8%). Asian Working Group for Sarcopenia (AWGS) aims to promote sarcopenia research.

Which distribution channel segment is dominating the sarcopenia treatment market?

The sarcopenia treatment market, based on distribution channel, is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held a substantial market share in 2022. However, the online channels segment is predicted to register the fastest CAGR during 2022–2030.

Which treatment type segment is dominating the sarcopenia treatment market?

The sarcopenia treatment market, based on treatment type, is segmented into vitamin D and calcium supplements, protein supplements, vitamin B12 supplements, and others. The vitamin D and calcium supplements segment held the largest share of the market in 2022.

Which country is dominated the sarcopenia treatment market?

US holds the largest market share in sarcopenia treatment market. Sarcopenia prevalence varies with age and gender; elderly people residing in assisted living facilities or communities in the US are at a higher risk of developing this condition. According to the National Institute of Health, in 2019, the anticipated hospitalization cost for persons with sarcopenia in the US was US$ 40.4 billion. People with sarcopenia pay US$ 2,315 more for hospital visits than people with normal muscle mass and function every year on average; they are almost twice as likely to be hospitalized than people without sarcopenia.

Who are the major players in the sarcopenia treatment market?

The sarcopenia treatment market majorly consists of the players such as Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc., Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC among others.

What are the driving factors for the sarcopenia treatment market across the globe?

The factors that are driving growth of the market are upsurge in geriatric population and rise in malnutrition and vitamin deficiency among adults.

What is sarcopenia treatment?

The progressive loss of muscular mass, strength, and function is known as sarcopenia. The illness, which is most common in the elderly, is said to be brought on by ageing. Sarcopenia can significantly lower the quality of life by making it harder to carry out daily activities. It may result in the need for long-term care.
Sarcopenia has an impact on the musculoskeletal system and is a significant contributor to fractures, falls, and an increase in frailty. Hospital stays and surgical procedures brought on by these illnesses raise the possibility of complications, including death. Hormone supplements can be used to build muscle and treat sarcopenia. However, there aren't any FDA-approved drugs available right now to treat sarcopenia.

The List of Companies - Sarcopenia Treatment Market

  1. Abbott Laboratories          
  2. Bayer AG               
  3. Metagenics LLC   
  4. Nestle Health Science SA                
  5. Novartis AG          
  6. Pfizer Inc                
  7. Sanofi SA               
  8. Amway Corp        
  9. GSK Plc   
  10. Makers Nutrition LLC 

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports